Literature DB >> 23316256

Opioid Peptides: Potential for Drug Development.

Jane V Aldrich1, Jay P McLaughlin.   

Abstract

Opioid receptors are important targets for the treatment of pain and potentially for other disease states (e.g. mood disorders and drug abuse) as well. Significant recent advances have been made in identifying opioid peptide analogs that exhibit promising in vivo activity for treatment of these maladies. This review focuses on the development and evaluation of opioid peptide analogs demonstrating activity after systemic administration, and recent clinical evaluations of opioid peptides for possible therapeutic use.

Entities:  

Year:  2012        PMID： 23316256      PMCID： PMC3539827          DOI： 10.1016/j.ddtec.2011.07.007

Source DB:  PubMed          Journal:  Drug Discov Today Technol        ISSN： 1740-6749


  37 in total

1.  Opioid growth factor improves clinical benefit and survival in patients with advanced pancreatic cancer.

Authors:  Jill P Smith; Sandra I Bingaman; David T Mauger; Harold H Harvey; Laurence M Demers; Ian S Zagon
Journal:  Open Access J Clin Trials       Date:  2010-03-01

2.  Synthesis and structure-activity relationships of an orally available and long-acting analgesic peptide, N(alpha)-amidino-Tyr-D-Arg-Phe-MebetaAla-OH (ADAMB).

Authors:  Tadashi Ogawa; Tetsuhisa Miyamae; Kimie Murayama; Kaori Okuyama; Toru Okayama; Masaki Hagiwara; Shinobu Sakurada; Tadanori Morikawa
Journal:  J Med Chem       Date:  2002-11-07       Impact factor: 7.446

3.  Long-lasting antinociceptive effects of a novel dynorphin analogue, Tyr-D-Ala-Phe-Leu-Arg psi (CH(2)NH) Arg-NH(2), in mice.

Authors:  M Hiramatsu; K Inoue; A Ambo; Y Sasaki; T Kameyama
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

4.  Pharmacodynamic and pharmacokinetic characterization of poly(ethylene glycol) conjugation to met-enkephalin analog [D-Pen2, D-Pen5]-enkephalin (DPDPE).

Authors:  K A Witt; J D Huber; R D Egleton; M J Roberts; M D Bentley; L Guo; H Wei; H I Yamamura; T P Davis
Journal:  J Pharmacol Exp Ther       Date:  2001-08       Impact factor: 4.030

5.  In vivo characterization of MMP-2200, a mixed δ/μ opioid agonist, in mice.

Authors:  John J Lowery; Tyler J Raymond; Denise Giuvelis; Jean M Bidlack; Robin Polt; Edward J Bilsky
Journal:  J Pharmacol Exp Ther       Date:  2010-11-30       Impact factor: 4.030

6.  Gene therapy for pain: results of a phase I clinical trial.

Authors:  David J Fink; James Wechuck; Marina Mata; Joseph C Glorioso; James Goss; David Krisky; Darren Wolfe
Journal:  Ann Neurol       Date:  2011-07-27       Impact factor: 10.422

7.  A Phase II, multicenter, randomized, double-blind, placebo-controlled crossover study of CJC-1008--a long-acting, parenteral opioid analgesic--in the treatment of postherpetic neuralgia.

Authors:  Mark S Wallace; Dwight Moulin; A J M Clark; Ronald Wasserman; Ann Neale; Patricia Morley-Forster; Jean-Paul Castaigne; Sam Teichman
Journal:  J Opioid Manag       Date:  2006 May-Jun

8.  Orally administered H-Dmt-Tic-Lys-NH-CH2-Ph (MZ-2), a potent mu/delta-opioid receptor antagonist, regulates obese-related factors in mice.

Authors:  Ewa D Marczak; Yunden Jinsmaa; Page H Myers; Terry Blankenship; Ralph Wilson; Gianfranco Balboni; Severo Salvadori; Lawrence H Lazarus
Journal:  Eur J Pharmacol       Date:  2009-07-01       Impact factor: 4.432

9.  Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist.

Authors:  Raffaella Vergura; Gianfranco Balboni; Barbara Spagnolo; Elaine Gavioli; David G Lambert; John McDonald; Claudio Trapella; Lawrence H Lazarus; Domenico Regoli; Remo Guerrini; Severo Salvadori; Girolamo Caló
Journal:  Peptides       Date:  2007-10-23       Impact factor: 3.750

10.  Analgesic efficacy of peripheral kappa-opioid receptor agonist CR665 compared to oxycodone in a multi-modal, multi-tissue experimental human pain model: selective effect on visceral pain.

Authors:  Lars Arendt-Nielsen; Anne E Olesen; Camilla Staahl; Frédérique Menzaghi; Sherron Kell; Gilbert Y Wong; Asbjørn M Drewes
Journal:  Anesthesiology       Date:  2009-09       Impact factor: 7.892
View more
  19 in total

1.  Synthesis and opioid receptor binding of indium (III) and [111In]-labeled macrocyclic conjugates of diprenorphine: novel ligands designed for imaging studies of peripheral opioid receptors.

Authors:  Shefali Srivastava; Emily A Fergason-Cantrell; Roger I Nahas; John R Lever
Journal:  Tetrahedron       Date:  2016-08-04       Impact factor: 2.457

2.  Novel Dimethyltyrosine-Tetrahydroisoquinoline Peptidomimetics with Aromatic Tetrahydroisoquinoline Substitutions Show in Vitro Kappa and Mu Opioid Receptor Agonism.

Authors:  Deanna Montgomery; Jessica P Anand; Nicholas W Griggs; Thomas J Fernandez; Joshua G Hartman; Ashley A Sánchez-Santiago; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  ACS Chem Neurosci       Date:  2019-07-01       Impact factor: 4.418

3.  Analgesic efficacy and safety of DALDA peptide analog delivery to the brain using oil-in-water nanoemulsion formulation.

Authors:  Lipa Shah; Praveen Kulkarni; Craig Ferris; Mansoor M Amiji
Journal:  Pharm Res       Date:  2014-05-03       Impact factor: 4.200

4.  Antinociceptive activity of thiazole-containing cyclized DAMGO and Leu-(Met) enkephalin analogs.

Authors:  Hannah M Harris; Shainnel O Eans; Michelle L Ganno; Jennifer C Davis; Colette T Dooley; Jay P McLaughlin; Adel Nefzi
Journal:  Org Biomol Chem       Date:  2019-05-16       Impact factor: 3.876

5.  The macrocyclic peptide natural product CJ-15,208 is orally active and prevents reinstatement of extinguished cocaine-seeking behavior.

Authors:  Jane V Aldrich; Sanjeewa N Senadheera; Nicolette C Ross; Michelle L Ganno; Shainnel O Eans; Jay P McLaughlin
Journal:  J Nat Prod       Date:  2013-01-17       Impact factor: 4.050

6.  The macrocyclic tetrapeptide [D-Trp]CJ-15,208 produces short-acting κ opioid receptor antagonism in the CNS after oral administration.

Authors:  Shainnel O Eans; Michelle L Ganno; Kate J Reilley; Kshitij A Patkar; Sanjeewa N Senadheera; Jane V Aldrich; Jay P McLaughlin
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

7.  χ-Space Screening of Dermorphin-Based Tetrapeptides through Use of Constrained Arylazepinone and Quinolinone Scaffolds.

Authors:  Olivier Van der Poorten; Robin Van Den Hauwe; Emilie Eiselt; Cecilia Betti; Karel Guillemyn; Nga N Chung; François Hallé; Frédéric Bihel; Peter W Schiller; Dirk Tourwé; Philippe Sarret; Louis Gendron; Steven Ballet
Journal:  ACS Med Chem Lett       Date:  2017-10-04       Impact factor: 4.345

8.  Sequence-Dependent Interfacial Adsorption and Permeation of Dipeptides across Phospholipid Membranes.

Authors:  Chenyu Wei; Andrew Pohorille
Journal:  J Phys Chem B       Date:  2017-10-16       Impact factor: 2.991

Review 9.  Novel Molecular Strategies and Targets for Opioid Drug Discovery for the Treatment of Chronic Pain.

Authors:  Keith M Olson; Wei Lei; Attila Keresztes; Justin LaVigne; John M Streicher
Journal:  Yale J Biol Med       Date:  2017-03-29

10.  Distinct roles of exogenous opioid agonists and endogenous opioid peptides in the peripheral control of neuropathy-triggered heat pain.

Authors:  Dominika Labuz; Melih Ö Celik; Andreas Zimmer; Halina Machelska
Journal:  Sci Rep       Date:  2016-09-08       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.